Literature DB >> 10446996

Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas.

H Harada1, K Nakagawa, S Iwata, M Saito, Y Kumon, S Sakaki, K Sato, K Hamada.   

Abstract

Recent studies have indicated that the loss of p16 is a frequent event in the progression of malignant gliomas. The loss of p16 promotes the acquisition of malignant characteristics in gliomas, which are among the most angiogenic of all human tumors. High-grade gliomas are distinguished from low-grade gliomas by intense angiogenesis in addition to their frequent loss of p16. New therapeutic strategies aimed at inhibiting tumor angiogenesis on the basis of molecular mechanisms are theoretically attractive. Here we evaluate the effect of p16 gene replacement on the angiogenesis of gliomas. Infection with a recombinant replication-defective adenovirus vector containing the cDNA of wild-type p16 significantly reduced the expression of vascular endothelial growth factor, which is thought to be a pivotal mediator of tumor angiogenesis, in p16-deleted glioma cells. Restoring wild-type p16 expression into p16-deleted glioma cells markedly inhibited angiogenesis induced by tumor cells in vivo. Furthermore, wild-type p16 inhibited neovascularization more potently than did wild-type p53 transfer. These findings indicate that the p16 gene plays an important role in the regulation of glioma angiogenesis, suggesting a novel function of the p16 gene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10446996

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

Review 1.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

2.  INK4a deletion results in improved kidney regeneration and decreased capillary rarefaction after ischemia-reperfusion injury.

Authors:  David H Lee; Jesse M Wolstein; Basu Pudasaini; Matthew Plotkin
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-28

3.  p16(Ink4a) inhibits histologic progression and angiogenic signaling in min colon tumors.

Authors:  Steven L Gibson; Amelie Boquoi; Tina Chen; Norman E Sharpless; Colleen Brensinger; Greg H Enders
Journal:  Cancer Biol Ther       Date:  2005-12-09       Impact factor: 4.742

4.  Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas.

Authors:  O Straume; L A Akslen
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

5.  Sense p16 and antisense uPAR bicistronic construct inhibits angiogenesis and induces glioma cell death.

Authors:  Narasimharao Nalabothula; Sajani S Lakka; Dzung H Dinh; Meena Gujrati; William C Olivero; Jasti S Rao
Journal:  Int J Oncol       Date:  2007-03       Impact factor: 5.650

Review 6.  Genes that regulate metastasis and angiogenesis.

Authors:  C P Webb; G F Vande Woude
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

7.  Aberrant cytological localization of p16 and CDK4 in colorectal epithelia in the normal adenoma carcinoma sequence.

Authors:  Po Zhao; Xin Mao; Ian C Talbot
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

8.  Expressing patterns of p16 and CDK4 correlated to prognosis in colorectal carcinoma.

Authors:  Po Zhao; Ying-Chuan Hu; Ian C Talbot
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

9.  Assessment of tumor angiogenesis as a prognostic factor of survival in patients with oligodendroglioma.

Authors:  H Quon; A Hasbini; J Cougnard; L Djafari; C Lacroix; B Abdulkarim
Journal:  J Neurooncol       Date:  2009-07-19       Impact factor: 4.130

Review 10.  Angiogenesis factors in gliomas: a new key to tumour therapy?

Authors:  Rolf Mentlein; Janka Held-Feindt
Journal:  Naturwissenschaften       Date:  2003-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.